How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?
Aza/ven patients had better EFS/QoL with a greater proportion of patients who successfully got to a stem cell transplant. Provided that the OS data is yet to mature, do these results change your current clinical practice?
Community PollStarted
Which fit patients will you offer aza/ven for newly diagnosed AML in lieu of intensive induction chemotherapy in light of PARADIGM results from ASH 2025?
33 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Hematology · University of Chicago
Answered on · Updated on
It was very exciting to see PARADIGM presented as a plenary at ASH, and I look forward to the manuscript! Interpreting the findings in the context of the enrolled patients is very important. The median age of enrolled patients was approximately 65 years in both arms, and ~75% of enrolled patients ha...
Join for free or sign in to see the full answer